- Ahi Evran Tıp Dergisi
- Cilt: 9 Sayı: 3
- Levels of YKL-40 in Cerebrospinal Fluid and Serum of Newly Diagnosed Patients with Relapsing-Remitti...
Levels of YKL-40 in Cerebrospinal Fluid and Serum of Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis
Authors : Serkan Kırbaş, Aynur Kırbaş, Medine Cumhur Cüre
Pages : 346-351
Doi:10.46332/aemj.1640948
View : 33 | Download : 88
Publication Date : 2025-12-22
Article Type : Research Paper
Abstract :Purpose: Chitinase-3-like protein 1 (CHI3L1 or YKL-40), novel inflammatory glycoprotein predominantly produced by reactive astrocytes. The aim of this study was to investigate YKL-40 levels in serum and cerebrospinal fluid (CSF) of newly diagnosed relapsingremitting multiple sclerosis (RRMS) patients. Materials and Methods: This study was conducted at the Neurology Clinic of Recep Tayyip Erdogan University Faculty of Medicine Training and Research Hospital between October 2012 and November 2016. A total of 50 participants, including 30 newly diagnosed and untreated RRMS patients (18 females, 12 males, age range 18-40 year) and 20 controls (12 females, 8 males, age range 20-40 year) were included in the study. CSF and serum YKL-40 levels of RRMS patients and controls were measured by ELISA. Results: CSF YKL-40 levels of RRMS patients were significantly higher than in controls. (respectively,168.8±28.3 ng/ml and 70.1±14.3 ng/ml, p<0.001). However, no significant differences were detected in serum YKL-40 levels between RRMS patients and controls. Serum YKL-40 levels were 51.2±12.1 ng/ml in RRMS patients and 46.8±8.2 ng/ml in controls (p=0.102). There were no correlation between serum and CSF YKL-40 activity in patients with RRMS (r=0.134 p=0.308). Conclusion: Our study supports the activation microglial in the early stages of newly diagnosed RRMS, as evidenced by elevated CSF YKL-40 levels. These findings should be corroborated by larger-scale clinical studies employing more specific glial inflammatory biomarkers. This may pave the way for the future use of drugs targeting glial inflammation in the early treatment of RRMS patients.Keywords : biyobelirteç, kitinaz-3 benzeri protein 1, multiple skleroz
ORIGINAL ARTICLE URL